Researchers at Washington University School of Medicine in St. Louis have shown that mRNA cancer vaccines can still trigger potent anti-tumor responses even when a key immune cell type traditionally thought essential is absent, challenging long-held assumptions about how these vaccines work.
The study, published April 15 in Nature, found that in mice lacking conventional dendritic cell type 1 (cDC1) — cells long considered critical for priming cytotoxic T cells against tumors and viruses — mRNA vaccines still generated strong CD8+ T cell responses capable of destroying cancer cells. This resilience occurred because a closely related subset, cDC2 dendritic cells, could independently activate tumor-killing T cells through an unconventional pathway not seen with other vaccine types.
Scientists had assumed that cDC1 cells were indispensable for mRNA vaccines to stimulate CD8+ T cells, based on their established role in cross-presenting antigens via MHC-I molecules — a process vital for cytotoxic immunity in viral infections and traditional vaccines. But when researchers genetically removed cDC1 cells and disrupted the WDFY4-dependent cross-presentation pathway, CD8+ T cell activation persisted, revealing a previously unrecognized redundancy in dendritic cell function.
Further analysis showed that both cDC1 and cDC2 subsets could prime CD8+ T cells on their own, though the resulting T cells displayed distinct phenotypic profiles. Despite these differences, both types effectively mediated anti-tumor immunity and established immunological memory, indicating that mRNA–LNP platforms engage a more flexible and adaptable immune response than previously understood.
The study also highlighted the role of “cross-dressing,” a process in which dendritic cells acquire pre-formed peptide–MHC-I complexes directly from non-hematopoietic cells, bypassing the need for internal antigen processing. This mechanism appeared to contribute significantly to the observed T cell priming, particularly in the absence of classical cross-presentation pathways.
Kenneth M. Murphy, MD, PhD, senior author and Eugene Opie Centennial Professor of Pathology & Immunology at WashU Medicine, emphasized the practical implications: “There is a lot of interest in applying the mRNA vaccine approaches used during the COVID-19 pandemic to the problem of inducing anti-tumor immunity. By dissecting which immune cells are involved and how they coordinate the response, we’re offering vaccine developers additional mechanistic insights to consider in optimizing these vaccines against tumor proteins.”
For more on this story, see mRNA Cancer Vaccines: New Immune Pathways Discovered.
The findings come as mRNA cancer vaccines advance in clinical trials for melanoma, small cell lung cancer, and bladder cancer, building on the platform’s proven success in infectious disease. Understanding these alternative activation routes could help refine vaccine design to improve efficacy, broaden accessibility, and overcome potential resistance mechanisms in patients with varying immune profiles.
How mRNA vaccines bypass traditional antigen presentation to activate killer T cells
Instead of relying solely on dendritic cells to process and present tumor antigens via MHC-I, mRNA vaccines can leverage cross-dressing, where dendritic cells acquire ready-made antigen complexes from other cells. This shortcut allows CD8+ T cell activation to proceed even when conventional pathways are disrupted, offering a novel explanation for the vaccines’ resilience in genetically modified mouse models.
Why the phenotypic differences in primed T cells matter for long-term immunity
Even though cDC1- and cDC2-primed CD8+ T cells both attacked tumors effectively, they exhibited distinct surface markers and functional traits, suggesting variations in durability, tissue homing, or recall potential. These differences could influence how well immune responses persist after vaccination or whether they adapt to immunosuppressive tumor microenvironments — factors critical for durable cancer control.
This follows our earlier report, Universal Cancer Vaccine Shows Promise in Eliminating Tumors in Mice | New mRNA Breakthrough.
What this means for the next generation of cancer vaccine design
Vaccine developers may now consider targeting multiple dendritic cell subsets or enhancing cross-dressing mechanisms to ensure reliable T cell priming regardless of individual patient variations in cDC1 availability or function. This adaptability could improve response rates in clinical settings where immune heterogeneity often limits vaccine efficacy.
Does this mean mRNA cancer vaccines will work better in people with low cDC1 levels?
The study suggests mRNA vaccines may retain effectiveness in individuals with reduced cDC1 function due to age, genetics, or disease, as cDC2 cells and cross-dressing can compensate — but human data are still needed to confirm this.
Are cDC2 cells as effective as cDC1 cells for triggering anti-tumor immunity?
In the mouse models, cDC2-primed CD8+ T cells showed comparable tumor-killing ability and memory formation to those primed by cDC1, though their phenotypic differences may affect behavior in complex tumor environments.
Could enhancing cross-dressing improve mRNA vaccine performance?
The researchers identified cross-dressing as a significant contributor to T cell priming, implying that strategies to boost this process — such as modulating lipid nanoparticle delivery or targeting specific cell interactions — might strengthen vaccine-induced immunity.
Will these findings change how mRNA cancer vaccines are tested in clinical trials?
While the results are mechanistic and derived from mouse models, they highlight immune biomarkers — like cDC2 activity or cross-dressing signatures — that could be monitored in early-phase trials to better understand response variability and guide dose or formulation adjustments.